SEATTLE, March 12 /PRNewswire/ -- Immunex Corporation (Nasdaq: IMNX)
announced today that the company's Board of Directors has elected
Robert J. Herbold to serve on the Board. His position expands the independent
membership of the Board.
"Bob is known as an outstanding leader, as is evidenced by his
contributions at companies recognized around the world for their marketing,
technology and operating excellence," said Immunex chairman and chief
executive officer, Ed Fritzky. "He brings to Immunex added perspective in
leading a high-growth, blockbuster business."
Herbold, 58, recently retired from Microsoft Corporation as executive vice
president and chief operating officer. In this capacity, he was responsible
for the worldwide operation at Microsoft, including finance, manufacturing,
distribution, information systems, human resources, corporate services and
corporate privacy/security.
"At Microsoft, while experiencing an explosive five-fold increase in
revenue in six years, Bob was able to not only meet the operational needs of
that growth but also yield an incredible nine-fold increase in profits," said
Fritzky. "That experience will be a real asset for Immunex."
Prior to joining Microsoft in 1994, Herbold was senior vice president of
advertising and information systems at The Procter & Gamble Company, where he
oversaw all aspects of brand management.
Mr. Herbold has a bachelor of science degree in mathematics from the
University of Cincinnati and both a master's degree in mathematics and a
Ph.D. in computer science from Case Western Reserve University. He is on the
Board of Directors of Weyerhaeuser Company, Agilent Technologies, and Terabeam
Networks.
Immunex Corporation is a leading biopharmaceutical company dedicated to
improving lives through immune system science innovations.
NOTE: This news release contains forward-looking statements that involve
risks and uncertainties, including risks associated with clinical development,
regulatory approvals, our reliance on third-party manufacturers, product
commercialization and other risks described from time to time in the SEC
reports filed by Immunex, including the most recently filed Form 10-Q. An
electronic version of this news release -- as well as additional information
about Immunex of interest to investors, customers, future employees and
patients -- is available on the Immunex website at http://www.immunex.com.
SOURCE Immunex Corporation
 back to top
Related links:
http://www.immunex.com
Company News On-Call:
http://www.prnewswire.com/comp/434644.html or fax,
800-758-5804, ext. 434644
CONTACT:
Robin Shapiro of Immunex Corporation,
206-389-4040
|
